Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative
Introduction Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC. Methods Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome. Results In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5–20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125. Conclusions Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Annals of surgical oncology - 31(2024), 5 vom: 03. Feb., Seite 3314-3324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fackche, Nadege T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© Society of Surgical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1245/s10434-024-14890-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055426808 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055426808 | ||
| 003 | DE-627 | ||
| 005 | 20240406064707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1245/s10434-024-14890-0 |2 doi | |
| 035 | |a (DE-627)SPR055426808 | ||
| 035 | |a (SPR)s10434-024-14890-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.81 |2 bkl | ||
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Fackche, Nadege T. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Society of Surgical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC. Methods Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome. Results In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5–20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125. Conclusions Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association. | ||
| 700 | 1 | |a Schmocker, Ryan K. |e verfasserin |4 aut | |
| 700 | 1 | |a Nudotor, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Kubi, Boateng |e verfasserin |4 aut | |
| 700 | 1 | |a Cloyd, Jordan M. |e verfasserin |4 aut | |
| 700 | 1 | |a Grotz, Travis E. |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Keith F. |e verfasserin |4 aut | |
| 700 | 1 | |a Dineen, Sean P. |e verfasserin |4 aut | |
| 700 | 1 | |a Veerapong, Jula |e verfasserin |4 aut | |
| 700 | 1 | |a Baumgartner, Joel M. |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Callisia N. |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sameer H. |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Gregory C. |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Laura A. |e verfasserin |4 aut | |
| 700 | 1 | |a Pokrzywa, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Abbott, Daniel E. |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Byrne |e verfasserin |4 aut | |
| 700 | 1 | |a Staley, Charles A. |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Mohammad Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Fabian M. |e verfasserin |4 aut | |
| 700 | 1 | |a Greer, Jonathan B. |e verfasserin |0 (orcid)0000-0001-8968-9710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d Springer International Publishing, 1994 |g 31(2024), 5 vom: 03. Feb., Seite 3314-3324 |w (DE-627)SPR009913947 |w (DE-600)2074021-9 |x 1534-4681 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:5 |g day:03 |g month:02 |g pages:3314-3324 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1245/s10434-024-14890-0 |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.81 |q VZ |
| 936 | b | k | |a 44.65 |q VZ |
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 5 |b 03 |c 02 |h 3314-3324 | ||